Brokers Issue Forecasts for Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Analysts at Chardan Capital issued their FY2025 EPS estimates for Prothena in a note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li anticipates that the biotechnology company will post earnings per share of ($3.25) for the year. Chardan Capital currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The company had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. Bank of America lowered their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. Piper Sandler raised their price target on Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $48.00 price objective on shares of Prothena in a research report on Friday, February 21st. Finally, Oppenheimer increased their target price on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $55.00.

Prothena Price Performance

Shares of PRTA opened at $13.37 on Thursday. The stock has a market capitalization of $719.67 million, a PE ratio of -5.81 and a beta of -0.02. The business’s fifty day moving average price is $14.33 and its 200 day moving average price is $15.68. Prothena has a 12-month low of $11.70 and a 12-month high of $26.36.

Institutional Trading of Prothena

Hedge funds have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC grew its stake in shares of Prothena by 19.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 833 shares in the last quarter. Headlands Technologies LLC grew its position in Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in Prothena during the 4th quarter valued at about $145,000. Purkiss Capital Advisors LLC acquired a new position in Prothena during the 4th quarter valued at about $149,000. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Prothena during the 4th quarter worth about $159,000. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.